Ultragenyx Pharmaceutical RARE Product — Sales Reserves Adjustments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept rare:SalesReservesAdjustments.
The official record: Ultragenyx Pharmaceutical’s 10-K, filed February 18, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ultragenyx Pharmaceutical's product — sales reserves adjustments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ultragenyx Pharmaceutical's product — sales reserves adjustments?
- Ultragenyx Pharmaceutical (RARE) reported product — sales reserves adjustments of -$1M in Q4 2025.
- How has Ultragenyx Pharmaceutical's product — sales reserves adjustments changed year-over-year?
- Ultragenyx Pharmaceutical's product — sales reserves adjustments decreased by 500.0% year-over-year, from $250K to -$1M.
- What is the long-term trend for Ultragenyx Pharmaceutical's product — sales reserves adjustments?
- Over 4 years (2021 to 2025), Ultragenyx Pharmaceutical's product — sales reserves adjustments has grown at a 112.0% compound annual growth rate (CAGR), from $198K to -$4M.
- What does product — sales reserves adjustments mean?
- This metric reflects periodic changes to previously estimated sales reserve balances due to updated information or revisions in assumptions. It serves as a reconciliation item that highlights the volatility or accuracy of the company's revenue recognition estimates. Frequent or large adjustments may indicate uncertainty in the underlying commercial environment or estimation methodology.